1. Home
  2. List
Reference Patent

Reference - List

  • 80 Hits
  • Search Condition : Filter (MeSH = Carcinoma, Non-Small-Cell Lung / pathology)
Species Resource Title
Human and Animal Cells A549(RCB0098) Acyclic Retinoid Inhibits the EGFR/AKT Signaling Pathway and Cancels Cisplatin-resistant Cell Characteristics.
DNA material pCMV-VSV-G-RSV-Rev (RDB04393) , pCAG-HIVgp (RDB04394) BHLHE41/DEC2 Expression Induces Autophagic Cell Death in Lung Cancer Cells and Is Associated with Favorable Prognosis for Patients with Lung Adenocarcinoma.
Human and Animal Cells A549 Notch1 signaling controls cell proliferation, apoptosis and differentiation in lung carcinoma.
Human and Animal Cells EBC-1(RCB1965) Selective beta2-adrenoceptor agonist enhances sensitivity to cisplatin in non-small cell lung cancer cell line.
Human and Animal Cells LC-2/ad(RCB0440) HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.
Human and Animal Cells A549 , Lu-134-A(RCB0466) , Lu-135(RCB0468) Glycoproteomics approach for identifying Glycobiomarker candidate molecules for tissue type classification of non-small cell lung carcinoma.
Human and Animal Cells A549(RCB0098) Effects of histone deacetylase inhibitors Tricostatin A and Quisinostat on tight junction proteins of human lung adenocarcinoma A549 cells and normal lung epithelial cells.
Human and Animal Cells PC-9(RCB4455) A highly specific and sensitive massive parallel sequencer-based test for somatic mutations in non-small cell lung cancer.
Human and Animal Cells A549(RCB0098) , LC-2/ad(RCB0440) , RERF-LC-KJ(RCB1313) MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
Human and Animal Cells PC-9(RCB4455) Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC.
Human and Animal Cells PC-9(RCB4455) Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
Human and Animal Cells PC-9(RCB4455) Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
Human and Animal Cells PC-9(RCB4455) Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies.
Human and Animal Cells PC-9(RCB4455) Podoplanin-expressing cancer-associated fibroblasts inhibit small cell lung cancer growth.
Human and Animal Cells A549(RCB0098) , LC-2/ad(RCB0440) Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.
Human and Animal Cells PC-9(RCB4455) , RERF-LC-AI(RCB0444) 11β hydroxysteroid dehydrogenase 1: a new marker for predicting response to immune-checkpoint blockade therapy in non-small-cell lung carcinoma.
Human and Animal Cells RERF-LC-AI(RCB0444) , RERF-LC-KJ(RCB1313) RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition.
Human and Animal Cells PC-9(RCB4455) Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells.
Human and Animal Cells KP4(RCB1005) , EBC-1(RCB1965) Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.
Human and Animal Cells PC-9(RCB4455) ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.